Evidence map›Paper›PMID 35685959›Full record

ArticleEcancermedicalscience2022

The relationship between tumour infiltrating lymphocytes, Epstein-Barr virus and

Carlos Castañeda, Miluska Castillo, Luis Bernabe, Nancy Suarez, Matteo Fassan, Joselyn Sanchez, Katherine Tello, Raul Alatrista, Ivan Chavez, Eloy Ruiz and 8 more

Open access · goldAbstract read
In one paragraph

Article in Ecancermedicalscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Association betweenWorld journal of gastrointestinal oncology · 2024
    Article
  3. Article
  4. International journal of biological sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Carlos CastañedaFacultad de Ciencias de la Salud, Universidad Cientifica del Sur, Lima 15067, Peru.
Miluska CastilloDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Luis BernabeDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Nancy SuarezDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Matteo FassanDepartment of Medicine-DIMED, Surgical Pathology Unit, University of Padua, Padua 35122, Italy.
Joselyn SanchezDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Katherine TelloDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Raul AlatristaDepartamento de Investigación, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Ivan ChavezDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Eloy RuizDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Yaqueline BazanDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Fernando BarredaDepartamento de Especialidades Médicas, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Daniel ValdiviaDepartamento de Especialidades Médicas, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Wei MengDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Arnab ChakravartiDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Juvenal SanchezDepartamento de Patologia, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Luis TaxaDepartamento de Patologia, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Paola MontenegroDepartamento de Oncologia Medica, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
The Ohio State University Wexner Medical Center · USIstituto Oncologico Veneto · ITUniversidad Científica del Sur · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Epstein-Barr virus (EBV) and Methods: TIL evaluation in haematoxylin-eosin was performed by a pathologist and density of CD3, CD8 and CD163 positive (immunohistochemistry staining) immune cells was calculated with the use of digital pathology software. EBV infection was detected by Results: We included 98 resected GC Peruvian cases in our evaluation. Median TIL percentage was 30. The proportion of EBV+ detected by ISH was 24.1%, of EBV+ detected by qPCR was 41.8%, while 70% showed methylation of EBV-related genes, and 58.21% of cases were HP+. Younger age ( Conclusion: Lower CD8 density and HP+ predict longer OS. High TIL level is associated with EBV+ and methylation of EBV-related genes, while lower CD8 density is associated with HP+ GC.

Indexed as

Epstein–Barr virusHelicobacter pyloriin situ hybridisationlymphocytes

Identifiers

PMID35685959
PMCPMC9085163
OpenAlexW4214602812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.